TyraTech, Inc.

Head-Lice Preventative Shampoo Coming to US Market

RNS Number : 0029Y
TyraTech, Inc.
20 January 2014
 



 

20 January 2014

TyraTech, Inc.

("TyraTech" or the "Company")

 

Vamousse head lice preventative shampoo coming to market in the USA

 

TyraTech, Inc. (AIM: TYR and TYRU) a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce its pioneering, over-the-counter head lice preventative shampoo product, Vamousse™, is now listed with the USA Food and Drug Administration ("FDA") and will be available for sale in the USA from the end of Q1 2014.  The Vamousse Preventative Shampoo is a new product in the Vamousse range of head lice products and complements the Vamousse Treatment.

 

The Vamousse™ preventative shampoo product is targeting a new market, the prevention rather than the treatment of head lice infestation.  The product provides a unique solution to help prevent head lice infestation. The shampoo can be used on a regular basis to prevent head lice infestation in children in at-risk situations (sleep-overs, camps, sports, events with friends, etc.) as well as to protect the whole family when an infestation occurs in one of its members. TyraTech believes that this product has the potential to give it access to a new market segment for prevention and for routine use of the product whereas existing head lice treatments are only used on an emergency basis and only for individuals that are already infested.

 

In addition, the new Vamousse™ preventative shampoo product will enable TyraTech to further expand its market penetration by offering a larger range of products for both head lice treatment and prevention. TytraTech believes that the Vamousse Preventative Shampoo will be distributed initially on-line and in brick-and-mortar distributors in the USA.

 

Bruno Jactel, Chief Executive Officer, said: "We have been working diligently to accelerate the development of this breakthrough preventative head lice shampoo targeting a new and potentially significant market. We are delighted to announce that we are now FDA listed and ready to launch in the US market. This product will be available soon in traditional retail and internet-based distributors. We feel confident that TyraTech's unique and complete product offering will help us to establish a significant market presence. TyraTech believes it is well positioned to meet market expectations for 2014 revenues."

 

Further information on Vamousse is available on the Company's website at: 
http://www.tyratech.com/content/company-products/head-lice.asp

 

For further information please contact:

 

TyraTech Inc.
Alan Reade, Non-Executive Chairman
Bruno Jactel, Chief Executive Officer

                     Tel: +44 7841 978709
                      Tel: +1 919 415 4340

 

SPARK Advisory Partners Limited, Nominated Adviser

Matt Davis / Mark Brady

                        Tel: +44 20 3368 3551

 

Allenby Capital Limited , Joint Broker                                         

Chris Crawford

 

Whitman Howard Limited, Joint Broker

Ranald Mc-Gregor Smith / Niall Devins

 

Walbrook, Financial PR and IR
Bob Huxford /Guy McDougall (Public Relations)
Paul Cornelius (Investor Relations)

 

                       Tel: +44 20 3328 5656

 

 

Tel: +44 20 7087 4555

 

                                                                                       
             Tel: +44 20 7933 8792
             Tel: +44 20 7933 8794

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSTLIIALIS